Olanzapine News and Research

RSS

Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.

Risks of antipsychotic use in dementia extend beyond previous alerts, study shows

Antipsychotic use in people with dementia is associated with higher risks of a wide range of serious health outcomes compared with non-use, according to a new study from a collaboration across the Universities of Manchester, Nottingham, Edinburgh and Dundee.

23 Apr 2024

Study shows antipsychotic drugs increase health risks in dementia patients

Study found that antipsychotic drug use in dementia patients is linked to increased risks of stroke, heart failure, and other serious conditions.

18 Apr 2024

Antipsychotics for dementia associated with elevated risks of serious adverse outcomes

Antipsychotic use in people with dementia is associated with elevated risks of a wide range of serious adverse outcomes including stroke, blood clots, heart attack, heart failure, fracture, pneumonia, and acute kidney injury, compared with non-use, finds a study published by The BMJ today.

17 Apr 2024

Pharmacogenomics holds promise for personalized dementia therapies

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

8 Nov 2023

The association between breastfeeding, drug exposure, and infant outcomes: more research is needed

Researchers explored the data linking breastfeeding, infant outcomes, and drug exposure.

28 Apr 2023

New insight into the possible ASD-cardiometabolic diseases link

A study conducted by the Centers for Disease Control and Prevention (CDC) from 2009 to 2017 determined that approximately 1 in 44 children ages 3-17 are diagnosed with some form of autism spectrum disorder (ASD).

10 Mar 2023

Medical cannabis use reduces sleep disturbances caused by PTSD

Researchers assess the association between the use of medical cannabis and sleep.

21 Sep 2022

Temporo-spatial pharmacometabolomics method to evaluate microregional effect of OLZ on brain tissue

Announcing a new article publication from Acta Pharmaceutica Sinica B. The brain is the most advanced organ with various complex structural and functional microregions.

5 Sep 2022

Antipsychotic drugs associated with increase in risk of breast cancer

Researchers at Washington University School of Medicine in St. Louis have found that many commonly prescribed antipsychotic medications are associated with a significant increase in risk of breast cancer.

6 Dec 2021

Medications commonly prescribed for schizophrenia linked to cognitive impairment

Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.

18 May 2021

Study explains why antipsychotic medications lead to weight gain, promote metabolic syndrome

Why do patients who receive antipsychotic medications to manage schizophrenia and bipolar disorder quickly gain weight and develop prediabetes and hyperinsulemia?

15 Feb 2021

Olanzapine drug can help manage nausea and vomiting in patients with advanced cancer

Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy.

8 May 2020

How cannabis interacts with medications

A new practice guideline published in the journal CMAJ in February 2020 describes five types of drug interactions possible with the use of cannabis. Cannabis is a plant-derived drug containing the psychoactive ingredient delta-9-tetrahydrocannabinol (THC) and non-psychoactive cannabidiol (CBD). These cannabinoids are broken down by the liver enzymes cytochrome P450 C(YP)34A, and CYP2CC9.

2 Mar 2020

Protein SV2A levels could explain poor neuronal connections in schizophrenia

A team of researchers have found that persons with schizophrenia may have lower levels of certain specific proteins that show up on their brain scans. This could help as diagnostic tools, say experts. The new study titled, “Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats”, is published in the latest issue of the journal Nature Communications.

14 Jan 2020

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Olanzapine News and Research

Further Reading

Risks of antipsychotic use in dementia extend beyond previous alerts, study shows

Study shows antipsychotic drugs increase health risks in dementia patients

Antipsychotics for dementia associated with elevated risks of serious adverse outcomes

Pharmacogenomics holds promise for personalized dementia therapies

The association between breastfeeding, drug exposure, and infant outcomes: more research is needed

New insight into the possible ASD-cardiometabolic diseases link

Medical cannabis use reduces sleep disturbances caused by PTSD

Temporo-spatial pharmacometabolomics method to evaluate microregional effect of OLZ on brain tissue

Antipsychotic drugs associated with increase in risk of breast cancer

Medications commonly prescribed for schizophrenia linked to cognitive impairment

Study explains why antipsychotic medications lead to weight gain, promote metabolic syndrome

Olanzapine drug can help manage nausea and vomiting in patients with advanced cancer

How cannabis interacts with medications

Protein SV2A levels could explain poor neuronal connections in schizophrenia

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Medical cannabis provides relief across dozens of health symptoms, study shows

Researchers explore use of antipsychotic medications in older adults following heart surgery

Switching anti-psychotic drugs in first-episode schizophrenia patients does not improve clinical outcomes

Study: Antipsychotic treatment increases body fat and decreases insulin sensitivity in youth

Study examines link between antipsychotic treatment during pregnancy and gestational diabetes risk

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News